OCEA (Ocean Biomedical) Notes Receivable: $0.00 Mil (As of Mar. 2025)


What is Ocean Biomedical Notes Receivable?

Ocean Biomedical OCEA -66.67% Notes Receivable is $0.00 Mil as of Mar. 2025.

Ocean Biomedical's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

Ocean Biomedical Notes Receivable Related Terms

Ocean Biomedical Notes Receivable Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical Notes Receivable Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Ocean Biomedical Quarterly Data
Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ocean Biomedical Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Ocean Biomedical (OCEA) has a Notes Receivable of $0.00 Mil as of Mar. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Ocean Biomedical and its competitors.
Is Ocean Biomedical's Notes Receivable too high?
Ocean Biomedical's current Notes Receivable is $0.00 Mil.
How does Ocean Biomedical's Notes Receivable compare to SIGY and ENDV?
Ocean Biomedical's Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Ocean Biomedical and its competitors. Ocean Biomedical's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocean Biomedical stock overvalued right now?
Ocean Biomedical (OCEA) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current Notes Receivable is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.